<?xml version="1.0" encoding="UTF-8"?>
<p>IFNα is contraindicated in children with decompensated cirrhosis, cytopenias, and autoimmune disease. Side effects of IFNα treatment included fever and flu-like symptoms, behavioral disorders, gastrointestinal disorders, and neutropenia. Furthermore, IFNα was shown to temporarily affect growth. Pegylated interferon-alpha (PegIFN) has not yet been approved for the treatment of chronic hepatitis B in children.</p>
